Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
grade C 6.82 -1.59% -0.11
RDHL closed down 1.59 percent on Friday, June 5, 2020, on 69 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical RDHL trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish -1.59%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.59%
Spinning Top Other -1.59%
Fell Below 20 DMA Bearish -2.15%
20 DMA Support Bullish -4.48%
20 DMA Support Bullish -3.81%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Medicine Biopharmaceutical Autoimmune Diseases Inflammatory Bowel Disease Antibiotics Heart Failure Hypertension Gastroenterology Abdominal Pain Bacteria Crohn's Disease Nausea Treatment Of Inflammatory Bowel Disease Vomiting Treatment Of Hypertension Ventricular Dysfunction

Is RDHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.12
52 Week Low 3.2621
Average Volume 505,484
200-Day Moving Average 6.24
50-Day Moving Average 6.66
20-Day Moving Average 7.05
10-Day Moving Average 7.06
Average True Range 0.50
ADX 11.06
+DI 18.00
-DI 20.79
Chandelier Exit (Long, 3 ATRs ) 6.11
Chandelier Exit (Short, 3 ATRs ) 7.77
Upper Bollinger Band 7.39
Lower Bollinger Band 6.71
Percent B (%b) 0.17
BandWidth 9.68
MACD Line 0.07
MACD Signal Line 0.13
MACD Histogram -0.0637
Fundamentals Value
Market Cap 117.05 Million
Num Shares 17.2 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -2.77
Price-to-Sales 264.36
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.44
Resistance 3 (R3) 7.43 7.22 7.33
Resistance 2 (R2) 7.22 7.06 7.22 7.30
Resistance 1 (R1) 7.02 6.97 6.92 7.03 7.26
Pivot Point 6.81 6.81 6.76 6.81 6.81
Support 1 (S1) 6.61 6.65 6.51 6.62 6.38
Support 2 (S2) 6.40 6.56 6.40 6.34
Support 3 (S3) 6.20 6.40 6.31
Support 4 (S4) 6.21